Royal Philips: Philips SmartCT 3D image acquisition, visualization and measurement software for its Azurion Image Guided Therapy System receives FDA 510(k) clearance Intuitive, table-side touchscreen control offers interventionalists enhanced diagnostic confidence and streamlined workflows [1] Full control of image acquisition and analysis from within the sterile zone helps to avoid procedure disruption, saving time and allowing interventionalists to stay focused on their patients Amsterdam, the Netherlands - Royal Philips(NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced U.S. Food and Drug Administration 510 (k) clearance for its Philips SmartCT application software. SmartCT is a key component of Philips Image Guided Therapy System - Azurion - providing interventionalists with CT-like 3D images (Cone Beam CT) to support diagnosis, therapy planning, treatment and follow-up for interventional radiology procedures. Bringing intuitive touchscreen control of advanced 3D image acquisition, visualization, vessel/organ segmentation, and quantitative measurements to the table-side, within the interventional lab's sterile zone, SmartCT helps enhance clinical confidence, smooths workflows, and increases productivity. It includes software applications for angiography, neurology, soft-tissue imaging, and guidewire/catheter navigation, supporting a wide range of procedures such as the treatment of aneurysms, vascular diseases and liver tumors.